EndoSonics announces IVUS reimbursement
EndoSonics received good news last month when the American Medical Association released CPT codes that will enable physicians to be reimbursed for the diagnostic use of intravascular ultrasound (IVUS). The codes go into effect Jan. 1, 2000. Prior to the
EndoSonics received good news last month when the American Medical Association released CPT codes that will enable physicians to be reimbursed for the diagnostic use of intravascular ultrasound (IVUS). The codes go into effect Jan. 1, 2000. Prior to the AMAs announcement, clinicians could be paid for IVUS only when it was included in an arterial intervention.
The news should give EndoSonics a boost in its U.S. sales, which could counteract the disappointing European sales the company posted in the third quarter (end-September). EndoSonics reported revenues of $10.5 million, down 10.3% from 1998s $11.7 million (SCAN 10/13/99), which the Rancho Cordova, CA-based firm attributed to a decline in orders from European distributor Jomed International.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
